ePT--the Electronic Newsletter of Pharmaceutical Technology, Apr 7, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Apr 7, 2011
News
Pfizer’s Capsugel Fetches $2.375 Billion
By Rich Whitworth
After completing a strategic review of options for its Capsugel business, Pfizer announced on Apr. 04, 2011 that Kohlberg Kravis Roberts & Co L.P will acquire the pharmaceutical and dietary capsule company.
sanofi Completes Genzyme Acquisition
By Stephanie Sutton
sanofi-aventis has gained full control over Genzyme, bringing the much talked about acquisition deal between the two companies to a close.
J&J Reorganizes Consumer Group
By Erik Greb
Johnson & Johnson has instituted a new structure for its Consumer Group according to a Reuters report.
SOCMA Voices Concern over IST Provisions in Chemical-Site Security Measures
By Patricia Van Arnum
The Society of Chemical Manufacturers and Affiliates criticized the Secure Chemical Facilities Act, which would require chemical facilities to use inherently safer technology as part of chemical-site security measures.
Nigeria Looks to Simple Packaging Controls and International Cooperation to Curb Counterfeit Drugs
By Amy Ritter
Week of Apr. 7, 2011: Company and People Notes: ATMI Forms Distribution Pact with Finesse; AAIPharma Promotes Dean Shirazi; and More.
ATMI Forms Distribution Pact with Finesse; AAIPharma Promotes Dean Shirazi; and More.
Regulatory Roundup: New Web Search Feature on FDA.gov, Search for Product Recalls More Quickly
New Web Search Feature on FDA.gov, Search for Product Recalls More Quickly

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here